Skip to main content
SpringerLink
Log in

Homologous and Heterologous Covid-19 Booster Vaccinations Against SARS-CoV-2 Infection in the Elderly

  • Short Communication
  • Published:
Current Microbiology Aims and scope Submit manuscript

  • 1 Altmetric

Abstract

A third booster doses for the 2019 coronavirus disease (COVID-19) is widely used all over the world, especially in risky individuals, with the recommendation of WHO. The purpose of this study was to evaluate the effectiveness of mRNA (BNT162b2), and CoronaVac (Sinovac Biotech) vaccines as a reminder dose following two doses of CoronaVac against COVID-19 infection, serious illness, and mortality in the geriatric population aged 75 and older during the delta variant dominant period. Our study comprised 2730 individuals the age of 75 and older in total, of which 1082 (39.6%) were male and 1648 (60.4%) were female. The vaccine effectiveness (VE) of 2 doses of CoronaVac + 1 dose of BNT162b2 vaccine combination against COVID-19 was determined as 89.2% (95% Confidence interval (CI) 80.7–93.9%), while the VE of 3 doses of CoronaVac vaccine was determined as 80.4% (95% CI 60.5–90.2%). Geriatric patients who received three doses of CoronaVac vaccine did not need intensive care. No deaths were observed in the vaccinated groups. While the VE of vaccination with 2 doses of CoronaVac + 1 dose of BNT162b2 was 41.8% (95% CI 0–74.1%) against hospitalization, 64.4% (95% CI 0–94.7%) against intensive care unit admission, the VE of vaccination with three doses of the CoronaVac was 78.2% (95% CI 0–96.5%) against hospitalization. In conclusion, our research showed that, even with the emergence of viral variants, a third dose of the CoronaVac and BNT162b2 vaccines is highly effective against symptomatic SARS-CoV-2 infection. Third-dose vaccination regimens, including heterologous and homologous vaccines, can be an effective tool in controlling the COVID-19 pandemic and the emergence of new variants.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Data Availability

This article has all the data that was generated or evaluated during this investigation, and the data can be reproduced and is provided by the authors upon request.

Code Availability

Not applicable.

References

  1. Fiolet T, Kherabi Y, MacDonald C-J, Ghosn J, Peiffer-Smadja N (2022) Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. Clin Microbiol Infect 28(2):202–221. https://doi.org/10.1016/j.cmi.2021.10.005

    Article  CAS  PubMed  Google Scholar 

  2. Özüdoğru O, Acer Ö, Genç Bahçe Y (2022) Risks of catching COVID-19 according to vaccination status of healthcare workers during the SARS-CoV-2 Delta variant dominant period and their clinical characteristics. J Med Virol 94(8):3706–3713. https://doi.org/10.1002/jmv.27778

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Liu Y, Liu J, Xia H, Zhang X, Fontes-Garfias CR, Swanson KA, Cai H, Sarkar R, Chen W, Cutler M (2021) Neutralizing activity of BNT162b2-elicited serum. N Engl J Med 384(15):1466–1468. https://doi.org/10.1056/NEJMc2102017

    Article  PubMed  Google Scholar 

  4. Liu Y, Liu J, Xia H, Zhang X, Zou J, Fontes-Garfias CR, Weaver SC, Swanson KA, Cai H, Sarkar R (2021) BNT162b2-elicited neutralization against new SARS-CoV-2 spike variants. N Engl J Med 385(5):472–474. https://doi.org/10.1056/NEJMc2106083

    Article  PubMed  Google Scholar 

  5. Nanduri S, Pilishvili T, Derado G, Soe MM, Dollard P, Wu H, Li Q, Bagchi S, Dubendris H, Link-Gelles R (2021) Effectiveness of Pfizer-Pfizer-BioNTech and Moderna vaccines in preventing SARS-CoV-2 infection among nursing home residents before and during widespread circulation of the SARS-CoV-2 B. 1.617. 2 (Delta) variant-National Healthcare Safety Network, March 1–August 1, 2021. Morb Mortal Wkly Rep 70(34):1163–1166. https://doi.org/10.15585/mmwr.mm7034e3

    Article  CAS  Google Scholar 

  6. Rosenberg ES, Holtgrave DR, Dorabawila V, Conroy M, Greene D, Lutterloh E, Backenson B, Hoefer D, Morne J, Bauer U (2021) New COVID-19 cases and hospitalizations among adults, by vaccination status New York, May 3–July 25, 2021. Morb Mortal Wkly Rep 70(34):1150–1155. https://doi.org/10.15585/mmwr.mm7034e1

    Article  CAS  Google Scholar 

  7. Clemens SAC, Weckx L, Clemens R, Mendes AVA, Souza AR, Silveira MB, da Guarda SNF, de Nobrega MM, de Moraes Pinto MI, Gonzalez IG (2022) Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study. Lancet 399(10324):521–529. https://doi.org/10.1016/S0140-6736(22)00094-0

    Article  PubMed  PubMed Central  Google Scholar 

  8. WHO. World Health Organization (2021) Interim recommendations for heterologous COVID-19 vaccine schedules: interim guidance

  9. Lu S (2009) Heterologous prime–boost vaccination. Curr Opin Immunol 21(3):346–351. https://doi.org/10.1016/j.coi.2009.05.016

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C (2020) Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 383(27):2603–2615. https://doi.org/10.1056/NEJMoa2034577

    Article  CAS  PubMed  Google Scholar 

  11. Tanriover MD, Doğanay HL, Akova M, Güner HR, Azap A, Akhan S, Köse Ş, Erdinç FŞ, Akalın EH, Tabak ÖF (2021) Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet 398(10296):213–222. https://doi.org/10.1016/S0140-6736(21)01429-X

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Genç Bahçe Y, Acer Ö, Özüdoğru O (2023) Effectiveness of inactivated and mRNA COVID-19 vaccines against SARS-CoV-2 infection, severe disease and mortality in the geriatric population. Curr Microbiol 80(6):206. https://doi.org/10.1007/s00284-023-03322-z

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Acer Ö, Genc Bahce Y, Özüdoğru O (2022) Association of viral load with age, gender, disease severity, and death in severe acute respiratory syndrome coronavirus 2 variants. J Med Virol 94(7):3063–3069. https://doi.org/10.1002/jmv.27677

    Article  CAS  PubMed  Google Scholar 

  14. Özüdoğru O, Bahçe YG, Acer Ö (2023) SARS CoV-2 reinfection rate is higher in the Omicron variant than in the Alpha and Delta variants. Ir J Med Sci 192(2):751–756. https://doi.org/10.1007/s11845-022-03060-4

    Article  CAS  PubMed  Google Scholar 

  15. Volpe GJ, Vessoni SCS, Soares LB, Dos Santos MAAL, Braga PE, de Moraes GR, Covas DT (2023) Antibody response dynamics to CoronaVac vaccine and booster immunization in adults and the elderly: a long-term, longitudinal prospective study. IJID Regions 7:222–229. https://doi.org/10.1016/j.ijregi.2023.04.003

    Article  PubMed  PubMed Central  Google Scholar 

  16. Sonmezer MC, Dizman GT, Erul E, Sahin TK, Saricaoglu T, Alp A, Tanriover MD, Uzun O, Unal S, Akova M (2022) Relative vaccine effectiveness of the third dose of CoronaVac or BNT162b2 following a two-dose coronavac regimen: a prospective observational cohort study from an adult vaccine center in Turkey. Vaccines 10(7):1140. https://doi.org/10.3390/vaccines10071140

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Tütüncü M, Demir S, Arslan G, Dinç Ö, Şen S, Gündüz T, Uzunköprü C, Gümüş H, Tütüncü M, Akçin R (2023) mRNA versus inactivated virus COVID-19 vaccines in multiple sclerosis: humoral responses and protectivity-does it matter? Mult Scler Relat Disord 75:104761. https://doi.org/10.1016/j.msard.2023.104761

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Nordström P, Ballin M, Nordström A (2021) Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: a nationwide cohort study. Lancet Reg Health Eur 11:100249. https://doi.org/10.1016/j.lanepe.2021.100249

    Article  PubMed  PubMed Central  Google Scholar 

  19. Zhang R, Khong K-W, Leung K-Y, Liu D, Fan Y, Lu L, Chan P-C, Chen L, To KK-W, Chen H (2021) Antibody response of BNT162b2 and CoronaVac platforms in recovered individuals previously infected by COVID-19 against SARS-CoV-2 wild type and Delta variant. Vaccines 9(12):1442. https://doi.org/10.3390/vaccines9121442

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Khong K-W, Liu D, Leung K-Y, Lu L, Lam H-Y, Chen L, Chan P-C, Lam H-M, Xie X, Zhang R (2022) Antibody response of combination of BNT162b2 and CoronaVac platforms of COVID-19 vaccines against Omicron variant. Vaccines 10(2):160. https://doi.org/10.3390/vaccines10020160

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Gilbert PB, Montefiori DC, McDermott AB, Fong Y, Benkeser D, Deng W, Zhou H, Houchens CR, Martins K, Jayashankar L (2022) Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science 375(6576):43–50. https://doi.org/10.1126/science.abm3425

    Article  CAS  PubMed  Google Scholar 

  22. Niyomnaitham S, Jongkaewwattana A, Meesing A, Pinpathomrat N, Nanthapisal S, Hirankarn N, Siwamogsatham S, Kirdlarp S, Chaiwarith R, Lawpoolsri S (2023) Immunogenicity of a fractional or full third dose of AZD1222 vaccine or BNT162b2 messenger RNA vaccine after two doses of CoronaVac vaccines against the Delta and Omicron variants. Int J Infect Dis 129:19–31. https://doi.org/10.1016/j.ijid.2023.01.022

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Romero-Ibarguengoitia ME, Rivera-Salinas D, Hernández-Ruíz YG, Armendariz-Vázquez AG, González-Cantú A, Barco-Flores IA, González-Facio R, Montelongo-Cruz LP, Del Rio-Parra GF, Garza-Herrera MR (2022) Effect of the third dose of BNT162b2 vaccine on quantitative SARS-CoV-2 spike 1–2 IgG antibody titers in healthcare personnel. PLoS ONE 17(3):e0263942. https://doi.org/10.1371/journal.pone.0263942

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Lustig Y, Gonen T, Meltzer L, Gilboa M, Indenbaum V, Cohen C, Amit S, Jaber H, Doolman R, Asraf K (2022) Superior immunogenicity and effectiveness of the third compared to the second BNT162b2 vaccine dose. Nat Immunol 23(6):940–946. https://doi.org/10.1038/s41590-022-01212-3

    Article  CAS  PubMed  Google Scholar 

  25. Ranzani OT, Hitchings MD, Dorion M, D’Agostini TL, de Paula RC, de Paula OFP, de Moura Villela EF, Torres MSS, de Oliveira SB, Schulz W (2021) Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study. BMJ 374:n2015. https://doi.org/10.1136/bmj.n2015

    Article  PubMed  Google Scholar 

  26. Barda N, Dagan N, Cohen C, Hernán MA, Lipsitch M, Kohane IS, Reis BY, Balicer RD (2021) Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet 398(10316):2093–2100. https://doi.org/10.1016/S0140-6736(21)02249-2

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Accorsi EK, Britton A, Fleming-Dutra KE, Smith ZR, Shang N, Derado G, Miller J, Schrag SJ, Verani JR (2022) Association between 3 doses of mRNA COVID-19 vaccine and symptomatic infection caused by the SARS-CoV-2 Omicron and Delta variants. JAMA 327(7):639–651. https://doi.org/10.1001/jama.2022.0470

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Zeng G, Wu Q, Pan H, Li M, Yang J, Wang L, Wu Z, Jiang D, Deng X, Chu K (2022) Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials. Lancet Infect Dis 22(4):483–495. https://doi.org/10.1016/S1473-3099(21)00681-2

    Article  CAS  PubMed  Google Scholar 

  29. Jara A, Undurraga EA, Zubizarreta JR, González C, Pizarro A, Acevedo J, Leo K, Paredes F, Bralic T, Vergara V (2022) Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study. Lancet Glob Health 10(6):e798–e806. https://doi.org/10.1016/S2214-109X(22)00112-7

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

For this study, there was no institutional support.

Author information

Authors and Affiliations

  1. Department of Medical Microbiology, Medical Faculty, Siirt University, 56100, Siirt, Türkiye

    Ömer Acer

  2. Microbiology Laboratory, Siirt Training and Research Hospital, 56100, Siirt, Türkiye

    Yasemin Genç Bahçe

  3. Department of Internal Medicine, Medical Faculty, Erzincan Binali Yıldırım University, 24100, Erzincan, Türkiye

    Osman Özüdoğru

Authors
  1. Ömer Acer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yasemin Genç Bahçe
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Osman Özüdoğru
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

OA and YGB performed investigation, writing‐original draft preparation, reviewing, methodology, OÖ performed investigation, conceptualization, methodology, reviewing. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Ömer Acer.

Ethics declarations

Conflict of interest

The authors declare that they have no conflicts of interest.

Ethical Approval

The Siirt University Non-Interventional Clinical Research Ethics Committee approved this study in accordance with Helsinki (Decision Date: 10.14.2022, number: 2022/10/01/01).

Consent to Participate

All participants who were enrolled in the study signed the informed consent form.

Consent for Publication

Not applicable.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Acer, Ö., Genç Bahçe, Y. & Özüdoğru, O. Homologous and Heterologous Covid-19 Booster Vaccinations Against SARS-CoV-2 Infection in the Elderly. Curr Microbiol 81, 171 (2024). https://doi.org/10.1007/s00284-024-03689-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s00284-024-03689-7

Search

Navigation